Developer docs
API playgroundTry for free, no card

Search company profiles

Biolinco

Full company profile

uuid02m5pk8

Namestring
Biolinco
Legal namestring
Biolinco Inc.
Websiteurl
biolinco.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Biolinco is a privately held biotechnology services company founded in 2023 and headquartered in Baltimore, Maryland. The company provides high-throughput cell line development services to Contract Development and Manufacturing Organizations (CDMOs) and biopharmaceutical companies, targeting the critical bottleneck of clone selection for biologic drug manufacturing. Its core offering is the MATCH Platform, a barcoded cell line development platform that combines unique, heritable DNA barcodes with multi-omic characterization (FACS-based assays and sequencing) to screen thousands of Chinese Hamster Ovary (CHO) cell clones simultaneously in a single fed-batch run under manufacturing-relevant conditions.

Technically, the MATCH workflow assigns a unique DNA barcode to each cell line, pools thousands of barcoded clones into a manufacturing-scale fed-batch culture, characterizes productivity and quality for every clone in parallel, and then retrieves top clones with >99.8% on-target precision, outputting a manufacturing-ready cell line with a full performance dataset. The platform claims to screen >2,500x more clones per run than conventional 96-well plate methods, support libraries of >200,000 unique barcodes, and reduce cost per clone by 100-1,000x. Biolinco's scientific founders (Kent Rapp, Kevin Wen, Reza Kalhor, Michael Betenbaugh) are all PhD researchers from Johns Hopkins University, and the company has been backed by Johns Hopkins-affiliated accelerators (FastForward U, JHTV) and selected into the Techstars Spring 2026 cohort.

Commercially, Biolinco operates a direct enterprise sales model with quote-based, project-fee pricing on cell line development engagements. It has no publicly disclosed customers, revenue, or institutional funding rounds, and has not published pricing. Marketing is conducted through the company website, accelerator demo days (Techstars Spring 2026, JHU Innovation Summit, FastForward U Spark Showcase), and a direct contact form — indicating a company at an early, pre-commercial or pilot-stage phase focused on customer development and fundraising.

Short descriptiontext

Biolinco is a Baltimore-based biotech services company founded in 2023 that uses its MATCH Platform — combining DNA barcoding with multi-omic characterization — to provide high-throughput cell line development services to CDMOs and biopharmaceutical manufacturers seeking better clone selection.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBaltimore, United States
HQ citystring
Baltimore
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell line development, biopharmaceutical manufacturing, DNA barcoding technology, CHO cell screening, biologic drug development
Industry2 codes
PRIMARYHLAAAKAF
Process Development & Tech Transfer Services (upstream/downstream)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceutical Cell Line Development Services
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Cell Line Development Services
TypeProfessional Services
Description

Biolinco provides cell line development services to CDMOs and biopharmaceutical companies. The company screens cell lines for clients using their barcoded platform, generating revenue through service fees for custom cell line development projects.

biolinco.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Biolinco provides high-throughput cell line development services through its proprietary MATCH Platform, which uses DNA barcoding combined with multi-omic characterization to screen thousands of CHO cell clones simultaneously under real manufacturing conditions. The platform delivers manufacturing-ready cell lines with comprehensive performance datasets to CDMOs and biopharmaceutical companies, enabling better-informed clone selection decisions before scale-up.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Screens >2,500x more clones per run compared to conventional 96-well plate methods
+3 more records
Product overview1 text field

Biolinco offers a single unified platform — the MATCH Platform — for high-throughput cell line development services. The platform combines DNA barcoding with multi-omic characterization to screen thousands of barcoded CHO cell clones simultaneously under real manufacturing conditions. Biolinco provides cell line development services for CDMOs and biopharmaceutical companies, with the platform capable of screening over 200,000 unique barcodes per library, delivering 2,500x more clones screened per run compared to conventional 96-well plate methods.

Product and service1 record
1MATCH Platform
CategoryCell Line Development Services
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

One of the world's largest CDMOs with a long-established mammalian cell line development (e.g., GS Xceed) service for biopharma. Directly comparable as a CLD service provider to Biolinco's CDMO and biopharma customers, though operating at vastly greater scale and as part of a full-service CMC portfolio.

TypeBroad incumbent
Description

Supplies cell line development tools, media, and services used by CDMOs and biopharma for CHO-based biologics manufacturing. Comparable as a CLD-enabling technology and services provider serving the same customer base.

TypeDirect peer
Description

Developed single-cell screening and functional cell selection platforms used in cell line development and biologics discovery. Closely comparable in the technology play — using single-cell/functional screening to improve clone selection — though with a different hardware-centric delivery model.

4KBI Biologics
TypeDirect peer
Description

Mid-sized CDMO with cell line development, process development, and analytical services for biopharma. Comparable as a CLD-focused service provider to biopharma clients, more similar in scale and positioning than the mega-CDMOs.

TypeOthers
Description

Provides single-cell sequencing and multi-omic characterization platforms that overlap with Biolinco's underlying multi-omic characterization workflow. An enabling/adjacent technology provider rather than a direct CLD competitor.

TypeBroad incumbent
Description

Large-scale biologics CDMO with integrated cell line development, process development, and manufacturing services. Comparable as a CLD/CDMO competitor to Biolinco's biopharma customers.

TypeBroad incumbent
Description

Global CDMO providing cell line development, process development, and GMP manufacturing for biologics. Comparable as a CLD/CDMO competitor, particularly to mid-sized biopharma programs.

TypeBroad incumbent
Description

Global biologics CDMO offering cell line development, process development, and manufacturing. Overlaps with Biolinco on the CLD step for biopharma clients, but delivers it as part of a much broader end-to-end CMC platform.

TypeDirect peer
Description

Uses high-throughput single-cell screening and genomics to discover and engineer antibody and protein therapeutics. Comparable as a technology-driven, high-throughput biologics discovery/development company serving biopharma, though focused on antibody discovery rather than upstream CLD.

TypeBroad incumbent
Description

Major biologics CDMO offering cell line development and manufacturing services. Comparable as a CLD provider to CDMOs and biopharma, embedded within a broader CMC offering.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biolinco

Biopharmaceutical Cell Line Development Servicesbiolinco.com

Biolinco is a Baltimore-based biotech services company founded in 2023 that uses its MATCH Platform — combining DNA barcoding with multi-omic characterization — to provide high-throughput cell line development services to CDMOs and biopharmaceutical manufacturers seeking better clone selection.

What Biolinco does

Biolinco is a privately held biotechnology services company founded in 2023 and headquartered in Baltimore, Maryland. The company provides high-throughput cell line development services to Contract Development and Manufacturing Organizations (CDMOs) and biopharmaceutical companies, targeting the critical bottleneck of clone selection for biologic drug manufacturing. Its core offering is the MATCH Platform, a barcoded cell line development platform that combines unique, heritable DNA barcodes with multi-omic characterization (FACS-based assays and sequencing) to screen thousands of Chinese Hamster Ovary (CHO) cell clones simultaneously in a single fed-batch run under manufacturing-relevant conditions.

Technically, the MATCH workflow assigns a unique DNA barcode to each cell line, pools thousands of barcoded clones into a manufacturing-scale fed-batch culture, characterizes productivity and quality for every clone in parallel, and then retrieves top clones with >99.8% on-target precision, outputting a manufacturing-ready cell line with a full performance dataset. The platform claims to screen >2,500x more clones per run than conventional 96-well plate methods, support libraries of >200,000 unique barcodes, and reduce cost per clone by 100-1,000x. Biolinco's scientific founders (Kent Rapp, Kevin Wen, Reza Kalhor, Michael Betenbaugh) are all PhD researchers from Johns Hopkins University, and the company has been backed by Johns Hopkins-affiliated accelerators (FastForward U, JHTV) and selected into the Techstars Spring 2026 cohort.

Commercially, Biolinco operates a direct enterprise sales model with quote-based, project-fee pricing on cell line development engagements. It has no publicly disclosed customers, revenue, or institutional funding rounds, and has not published pricing. Marketing is conducted through the company website, accelerator demo days (Techstars Spring 2026, JHU Innovation Summit, FastForward U Spark Showcase), and a direct contact form — indicating a company at an early, pre-commercial or pilot-stage phase focused on customer development and fundraising.

Biolinco firmographics

Firmographics
Name
Biolinco
Legal name
Biolinco Inc.
Website
https://biolinco.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
1–10 employees
Short description
Biolinco is a Baltimore-based biotech services company founded in 2023 that uses its MATCH Platform — combining DNA barcoding with multi-omic characterization — to provide high-throughput cell line development services to CDMOs and biopharmaceutical manufacturers seeking better clone selection.
Ownership category
akta.pro rank

Biolinco industry classification

Industry
Product category
Biopharmaceutical Cell Line Development Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAKAF
Process Development & Tech Transfer Services (upstream/downstream)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Cell line development
  • Biopharmaceutical manufacturing
  • DNA barcoding technology
  • CHO cell screening
  • Biologic drug development

Where Biolinco is headquartered

Location

Headquarters

HQ city
Baltimore
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Biolinco business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Cell Line Development Services: Biolinco provides cell line development services to CDMOs and biopharmaceutical companies. The company screens cell lines for clients using their barcoded platform, generating revenue through service fees for custom cell line development projects.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Biolinco product offering

Product offering

Core offering

Biolinco provides high-throughput cell line development services through its proprietary MATCH Platform, which uses DNA barcoding combined with multi-omic characterization to screen thousands of CHO cell clones simultaneously under real manufacturing conditions. The platform delivers manufacturing-ready cell lines with comprehensive performance datasets to CDMOs and biopharmaceutical companies, enabling better-informed clone selection decisions before scale-up.

Product overview

Biolinco offers a single unified platform — the MATCH Platform — for high-throughput cell line development services. The platform combines DNA barcoding with multi-omic characterization to screen thousands of barcoded CHO cell clones simultaneously under real manufacturing conditions. Biolinco provides cell line development services for CDMOs and biopharmaceutical companies, with the platform capable of screening over 200,000 unique barcodes per library, delivering 2,500x more clones screened per run compared to conventional 96-well plate methods.

Differentiator

Problem solved

Functional benefit

Products and services

  • MATCH Platform

Quantifiable outcome

  • Screens >2,500x more clones per run compared to conventional 96-well plate methods
  • +3 more outcomes

Companies that use Biolinco

Customer profile

Segments2 records

Ideal customer profiles2 records

Biolinco technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Biolinco partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves4 records

Expansion highlights4 records

Biolinco competitors and assessment

Company assessment

Broad incumbents

  • Lonza: One of the world's largest CDMOs with a long-established mammalian cell line development (e.g., GS Xceed) service for biopharma. Directly comparable as a CLD service provider to Biolinco's CDMO and biopharma customers, though operating at vastly greater scale and as part of a full-service CMC portfolio.
  • Cytiva: Supplies cell line development tools, media, and services used by CDMOs and biopharma for CHO-based biologics manufacturing. Comparable as a CLD-enabling technology and services provider serving the same customer base.
  • Samsung Biologics: Large-scale biologics CDMO with integrated cell line development, process development, and manufacturing services. Comparable as a CLD/CDMO competitor to Biolinco's biopharma customers.
  • AGC Biologics: Global CDMO providing cell line development, process development, and GMP manufacturing for biologics. Comparable as a CLD/CDMO competitor, particularly to mid-sized biopharma programs.
  • WuXi Biologics: Global biologics CDMO offering cell line development, process development, and manufacturing. Overlaps with Biolinco on the CLD step for biopharma clients, but delivers it as part of a much broader end-to-end CMC platform.
  • FUJIFILM Diosynth Biotechnologies: Major biologics CDMO offering cell line development and manufacturing services. Comparable as a CLD provider to CDMOs and biopharma, embedded within a broader CMC offering.

Direct peers

  • Berkeley Lights (now PhenomeX): Developed single-cell screening and functional cell selection platforms used in cell line development and biologics discovery. Closely comparable in the technology play — using single-cell/functional screening to improve clone selection — though with a different hardware-centric delivery model.
  • KBI Biologics: Mid-sized CDMO with cell line development, process development, and analytical services for biopharma. Comparable as a CLD-focused service provider to biopharma clients, more similar in scale and positioning than the mega-CDMOs.
  • AbCellera Biologics: Uses high-throughput single-cell screening and genomics to discover and engineer antibody and protein therapeutics. Comparable as a technology-driven, high-throughput biologics discovery/development company serving biopharma, though focused on antibody discovery rather than upstream CLD.

Others

  • 10x Genomics: Provides single-cell sequencing and multi-omic characterization platforms that overlap with Biolinco's underlying multi-omic characterization workflow. An enabling/adjacent technology provider rather than a direct CLD competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Biolinco financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biolinco leadership team

Management profile

Number of profiles

Profiles4 records

Biolinco funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biolinco M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biolinco

What does Biolinco do?

Biolinco provides high-throughput cell line development services through its proprietary MATCH Platform, which uses DNA barcoding combined with multi-omic characterization to screen thousands of CHO cell clones simultaneously under real manufacturing conditions. The platform delivers manufacturing-ready cell lines with comprehensive performance datasets to CDMOs and biopharmaceutical companies, enabling better-informed clone selection decisions before scale-up.

Is Biolinco a public or private company?

Biolinco is a private company. It is classified as venture growth investor backed and is currently operating.

When was Biolinco founded?

Biolinco was founded in 2023. It employs 1 to 10 people.

Where is Biolinco based?

Biolinco is headquartered in Baltimore, United States, in the North America region.

How does Biolinco make money?

One revenue line is on record: cell Line Development Services.

Who are Biolinco's main competitors?

Broad incumbents on record are Lonza, Cytiva, Samsung Biologics, AGC Biologics, WuXi Biologics and FUJIFILM Diosynth Biotechnologies. Direct peers are Berkeley Lights (now PhenomeX), KBI Biologics and AbCellera Biologics. 10x Genomics is listed as an others.

Does Biolinco have an API?

No public API is recorded for Biolinco.

What industry is Biolinco in?

Biolinco's product category is Biopharmaceutical Cell Line Development Services. Its primary akta.pro industry code is HLAAAKAF, Process Development & Tech Transfer Services (upstream/downstream), with a secondary code of HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales